Use of recombinant activated factor VII in cardiac surgery for an effective treatment of severe intractable bleeding

Japanese Heart Journal

Volumn 45, Issue 5, 2004, Pages 855-860

  Vanek, Tomas ^a   Straka, Zbynek ^a   Hrabak, Jakub ^a   Jares, Martin ^a   Brucek, Peter Jan ^a   Votava, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Bleeding; Cardiac surgery; Recombinant activated factor VII

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; PROTHROMBIN; PROTHROMPLEX TOTAL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN;

ADULT; AGED; AORTA VALVE DISEASE; AORTA VALVE REPLACEMENT; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG USE; FEMALE; HEART SURGERY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MALE; MITRAL VALVE DISEASE; MITRAL VALVE REPLACEMENT; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME; AORTA VALVE; BLEEDING; HEART VALVE REPLACEMENT; MIDDLE AGED; MITRAL VALVE;

ADULT; AGED; AGED, 80 AND OVER; AORTIC VALVE; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; CORONARY ARTERY BYPASS; FACTOR VIIA; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS;

EID: 16544390848     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/jhj.45.855     Document Type: Article

References (11)

1. Nuttall GJ, Oliver WC, Santrach PJ, et al. Efficacy of a simple intraoperative transfusion algorithm for non-erythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001; 94: 773-81.
2. Despotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82: 13-21.
3. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996; 111: 1037-46.
4. Gallistl S, Cvirn G, Muntean W. Recombinant factor VIIa does not induce hypercoagulability in vitro. Thromb Haemost 1999; 81: 245-9.
5. Al Douri M, Shafi T, Al Khudairi D, et al. Effect of administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11: S121-7.
6. Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001; 93: 287-9.
7. Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003; 4:49-51.
8. Dietrich W, Spannagl M. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. Anesth Analg 2002; 94: 1369-71.
9. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhrage control in trauma. J Trauma 2001; 51: 431-8. discussion: 438-9.
10. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002; 49: S15-20.
11. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.